Application of the systematic review and bibliometric network analysis (SeBriNA) methodology contextualizes evidence. Part 2: Rituximab for non-Hodgkin's lymphoma

Journal of Clinical Epidemiology

Volumn 65, Issue 9, 2012, Pages 996-1009

  Kho, Michelle E ^a,b   Brouwers, Melissa C ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Bibliometrics; Evidence based medicine; Non Hodgkin's lymphoma; Publication bias; Rituximab; Systematic reviews

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; MONOCLONAL ANTIBODY; PLACEBO; PREDNISONE; RECOMBINANT GROWTH FACTOR; RECOMBINANT INTERFERON; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

BIBLIOGRAPHIC DATABASE; BIBLIOMETRICS; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL RESEARCH; CLUSTER ANALYSIS; COHORT ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EDITOR; EMBASE; EVIDENCE BASED MEDICINE; GRADE SCALE; HEALTH CARE QUALITY; HUMAN; MEDICAL DOCUMENTATION; MEDLINE; META ANALYSIS; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PEER REVIEW; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW AND BIBLIOMETRIC NETWORK ANALYSIS; TREATMENT RESPONSE;

EID: 84864286109     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2012.03.008     Document Type: Article

References (28)

1. Cancer Care Ontario drug formulary - Rituximab. 2005 Available at www.cancercare.on.ca/pdfchemo/rituximab-NHLlo.pdf. Accessed November 21, 2007.
2. J.W. Friedberg, M.E. Kho, E.M. Lepisto, M.A. Rodriguez, A. TerVeer, and A.S. LaCasce Evolution of Rituximab as "Standard" Therapy in Patients (pts) with Newly diagnosed follicular (FL), mantle cell (MCL), and diffuse large B cell (DLCL) non-Hodgkin's lymphoma (NHL) in 5 United States comprehensive cancer centers: an analysis from the national comprehensive cancer network (NCCN) NHL outcomes project [Meeting Abstract] Blood 104 2004 1391
3. D. Nicholas, and M. Ritchie Literature and bibliometrics 1978 Linnet Books Hamden, CT
4. G.R. Norman, and D.L. Streiner Biostatistics: the bare essentials 2nd ed. 2000 BC Decker Inc Hamilton, ON
5. D.L. Streiner, and G.R. Norman Health measurement scales: a practical guide to their development and use 3rd ed. 2003 Oxford University Press New York, NY
6. E. von Elm, G. Poglia, B. Walder, and M.R. Tramer Different patterns of duplicate publication: an analysis of articles used in systematic reviews JAMA 291 2004 974 980
7. G.H. Guyatt, A.D. Oxman, R. Kunz, G.E. Vist, Y. Falck-Ytter, H.J. Schunemann GRADE Working Group What is "quality of evidence" and why is it important to clinicians? Br Med J 336 2008 995 998
8. B. Coiffier, E. Lepage, J. Briere, R. Herbrecht, H. Tilly, and R. Bouabdallah CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma [see comment] N Engl J Med 346 4 2002 235 242
9. N. Porta, C. Bonet, and E. Cobo Discordance between reported intention-to-treat and per protocol analyses J Clin Epidemiol 60 7 2007 663 669
10. L. Wood, M. Egger, L.L. Gluud, K.F. Schulz, P. Juni, and D.G. Altman Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study Br Med J 336 7644 2008 601 605
11. B. Coiffier, E. Lepage, R. Herbrecht, H. Tilly, P. Solal-Celigny, and J.N. Munck Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): interim results of a randomized GELA trial [Meeting Abstract] Blood 96 11 2000 223A
12. T.E. Witzig, L.I. Gordon, F. Cabanillas, M.S. Czuczman, C. Emmanouilides, and R. Joyce Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma J Clin Oncol 20 2002 2453 2463
13. P. McLaughlin, A.J. Grillo-Lopez, B.K. Link, R. Levy, M.S. Czuczman, and M.E. Williams Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16 1998 2825 2833
14. A.J. Grillo-Lopez Rituximab (Rituxan/MabThera): the first decade (1993-2003) [Review] Expert Rev Anticancer Ther 3 2003 767 779
15. Health Canada Notices of compliance - biologics and radiopharmaceuticals for human use January 1-December 31, 2000 2000 Health Canada Available at http://www.hc-sc.gc.ca/dhp-mps/alt-formats/hpfb-dgpsa/txt/prodpharma/ bio2000et-eng.txt Accessed December 31, 2009
16. C.M. Ketcham, and J.M. Crawford The impact of review articles Lab Invest 87 12 2007 1174 1185
17. Reuters. Drug therapy may aid some lymphoma patients. The New York Times. 2000 December 4;Sect. 8.
18. P. Feugier, A. Van Hoof, C. Sebban, P. Solal-Celigny, R. Bouabdallah, and C. Ferme Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 23 2005 4117 4126
19. R.I. Fisher, M. LeBlanc, O.W. Press, D.G. Maloney, J.M. Unger, and T.P. Miller New treatment options have changed the survival of patients with follicular lymphoma J Clin Oncol 23 2005 8447 8452
20. G.H. Guyatt, A.D. Oxman, G.E. Vist, R. Kunz, Y. Falck-Ytter, and P. Alonso-Coello GRADE: an emerging consensus on rating quality of evidence and strength of recommendations Br Med J 336 7650 2008 924 926
21. M.S. Czuczman, A.J. Grillo-Lopez, C.A. White, M. Saleh, L. Gordon, and A.F. LoBuglio Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy J Clin Oncol 17 1999 268 276
22. B. Coiffier, C. Haioun, N. Ketterer, A. Engert, H. Tilly, and D. Ma Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study Blood 92 1998 1927 1932
23. D.G. Maloney, A.J. Grillo-Lopez, C.A. White, D. Bodkin, R.J. Schilder, and J.A. Neidhart IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma Blood 90 1997 2188 2195
24. D.G. Maloney, A.J. Grillo-Lopez, D.J. Bodkin, C.A. White, T.M. Liles, and I. Royston IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma [see comment] J Clin Oncol 15 1997 3266 3274
25. J.M. Vose, B.K. Link, M.L. Grossbard, M. Czuczman, A. Grillo-Lopez, and P. Gilman Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma J Clin Oncol 19 2001 389 397
26. L.D. Piro, C.A. White, A.J. Grillo-Lopez, N. Janakiraman, A. Saven, and T.M. Beck Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma Ann Oncol 10 1999 655 661
27. P. Colombat, G. Salles, N. Brousse, P. Eftekhari, P. Soubeyran, and V. Delwail Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation Blood 97 2001 101 106
28. T.A. Davis, D.K. Czerwinski, and R. Levy Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression Clin Cancer Res 5 1999 611 615